Endoscopic and Oncologic Outcomes of Endoscopic Resection for Superficial Esophageal Neoplasm.
- Author:
Do Hoon KIM
1
;
Hwoon Yong JUNG
;
Eun Jeong GONG
;
Ji Young CHOI
;
Ji Yong AHN
;
Mi Young KIM
;
Kwi Sook CHOI
;
Jeong Hoon LEE
;
Kee Don CHOI
;
Ho June SONG
;
Gin Hyug LEE
;
Jin Ho KIM
;
Young Soo PARK
;
Seunghee BAEK
Author Information
- Publication Type:Original Article ; Evaluation Studies
- Keywords: Esophageal neoplasms; Treatment outcome; Endoscopic resection
- MeSH: Aged; Aged, 80 and over; Disease-Free Survival; Dissection/*adverse effects/methods; Esophageal Neoplasms/pathology/*surgery; Esophageal Perforation/epidemiology/etiology; Esophageal Stenosis/epidemiology/etiology; Esophagoscopy/*adverse effects/methods; Female; Gastric Mucosa/surgery; Humans; Male; Middle Aged; Neoplasm Recurrence, Local/epidemiology; Postoperative Hemorrhage/epidemiology/etiology; Retrospective Studies; Treatment Outcome
- From:Gut and Liver 2015;9(4):470-477
- CountryRepublic of Korea
- Language:English
- Abstract: BACKGROUND/AIMS: Endoscopic resection (ER) of superficial esophageal neoplasm (SEN) is a technically difficult procedure. We investigated the clinical outcomes of ER for SEN to determine its feasibility and effectiveness. METHODS: Subjects who underwent ER for SEN at Asan Medical Center between December 1996 and December 2010 were eligible. The clinical features of patients and tumors, histopathological characteristics, adverse events, ER results and survival were investigated. RESULTS: A total of 129 patients underwent ER for 147 SENs. En bloc resection (EnR) was performed in 118 lesions (80.3%). Complete resection (CR) was accomplished in 128 lesions (86.5%), and curative resection (CuR) was performed in 118 lesions (79.7%). The EnR, CR, and CuR rates were significantly greater in the endoscopic submucosal dissection group when compared to those in the endoscopic resection group. Adverse events occurred in 22 patients (17.1%), including bleeding (n=2, 1.6%), perforation (n=12, 9.3%), and stricture (n=8, 6.2%). Local tumor recurrence occurred in 2.0% of patients during a median follow-up of 34.8 months. The 5-year overall and disease-specific survival rates were 94.0% and 97.5%, respectively. CONCLUSIONS: ER is a feasible and effective method for the treatment of SEN as indicated by favorable clinical outcomes.
